Bayer Healthcare
3 products tracked · names used in filings: Bayer Healthcare
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Mon 09 Nov 2026🇺🇸 FDA approval
FDA approves NDA221291, a new medicine
Bayer Healthcare; NDA221291; New molecular entity, Priority review · source
Fri 12 Jun 2026🇺🇸 FDA approval
FDA approves Ambelvist (gadoquatrane), a new medicine
Bayer Healthcare; NDA219627; New molecular entity; solution · source
Wed 19 Nov 2025🇺🇸 FDA approval
FDA approves Hyrnuo (sevabertinib), a new medicine
Bayer Healthcare; NDA219972; New molecular entity, Priority review; tablet · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | NDA221291 | Approved | 2026-11-09 |
| 🇺🇸 | Ambelvist gadoquatrane | Approved | 2026-06-12 |
| 🇺🇸 | Hyrnuo sevabertinib | Approved | 2025-11-19 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.